Astellas Pharma Statistics
Total Valuation
Astellas Pharma has a market cap or net worth of JPY 2.69 trillion. The enterprise value is 3.43 trillion.
Market Cap | 2.69T |
Enterprise Value | 3.43T |
Important Dates
The next estimated earnings date is Friday, April 25, 2025.
Earnings Date | Apr 25, 2025 |
Ex-Dividend Date | Mar 28, 2025 |
Share Statistics
Astellas Pharma has 1.79 billion shares outstanding. The number of shares has decreased by -0.88% in one year.
Current Share Class | n/a |
Shares Outstanding | 1.79B |
Shares Change (YoY) | -0.88% |
Shares Change (QoQ) | -0.44% |
Owned by Insiders (%) | 0.01% |
Owned by Institutions (%) | 58.47% |
Float | 1.79B |
Valuation Ratios
PE Ratio | n/a |
Forward PE | 21.00 |
PS Ratio | 1.44 |
PB Ratio | 1.80 |
P/TBV Ratio | n/a |
P/FCF Ratio | 21.08 |
P/OCF Ratio | n/a |
PEG Ratio | 0.19 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 8.62, with an EV/FCF ratio of 26.85.
EV / Earnings | -59.64 |
EV / Sales | 1.83 |
EV / EBITDA | 8.62 |
EV / EBIT | 17.37 |
EV / FCF | 26.85 |
Financial Position
The company has a current ratio of 1.04, with a Debt / Equity ratio of 0.61.
Current Ratio | 1.04 |
Quick Ratio | 0.73 |
Debt / Equity | 0.61 |
Debt / EBITDA | 2.29 |
Debt / FCF | 7.17 |
Interest Coverage | 11.16 |
Financial Efficiency
Return on equity (ROE) is -3.83% and return on invested capital (ROIC) is 5.24%.
Return on Equity (ROE) | -3.83% |
Return on Assets (ROA) | 3.67% |
Return on Invested Capital (ROIC) | 5.24% |
Return on Capital Employed (ROCE) | 8.72% |
Revenue Per Employee | 126.58M |
Profits Per Employee | -3.89M |
Employee Count | 14,754 |
Asset Turnover | 0.55 |
Inventory Turnover | 1.35 |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -10.66% in the last 52 weeks. The beta is 0.16, so Astellas Pharma's price volatility has been lower than the market average.
Beta (5Y) | 0.16 |
52-Week Price Change | -10.66% |
50-Day Moving Average | 1,481.21 |
200-Day Moving Average | 1,614.06 |
Relative Strength Index (RSI) | 58.93 |
Average Volume (20 Days) | 6,614,750 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Astellas Pharma had revenue of JPY 1.87 trillion and -57.43 billion in losses. Loss per share was -32.07.
Revenue | 1.87T |
Gross Profit | 1.52T |
Operating Income | 200.46B |
Pretax Income | -77.98B |
Net Income | -57.43B |
EBITDA | 400.55B |
EBIT | 200.46B |
Loss Per Share | -32.07 |
Balance Sheet
The company has 179.87 billion in cash and 915.36 billion in debt, giving a net cash position of -735.50 billion or -410.87 per share.
Cash & Cash Equivalents | 179.87B |
Total Debt | 915.36B |
Net Cash | -735.50B |
Net Cash Per Share | -410.87 |
Equity (Book Value) | 1.49T |
Book Value Per Share | 834.64 |
Working Capital | 51.36B |
Cash Flow
In the last 12 months, operating cash flow was 165.42 billion and capital expenditures -37.83 billion, giving a free cash flow of 127.58 billion.
Operating Cash Flow | 165.42B |
Capital Expenditures | -37.83B |
Free Cash Flow | 127.58B |
FCF Per Share | 71.27 |
Margins
Gross margin is 81.50%, with operating and profit margins of 10.73% and -3.07%.
Gross Margin | 81.50% |
Operating Margin | 10.73% |
Pretax Margin | -4.18% |
Profit Margin | -3.07% |
EBITDA Margin | 21.45% |
EBIT Margin | 10.73% |
FCF Margin | 6.83% |
Dividends & Yields
This stock pays an annual dividend of 74.00, which amounts to a dividend yield of 4.95%.
Dividend Per Share | 74.00 |
Dividend Yield | 4.95% |
Dividend Growth (YoY) | 5.71% |
Years of Dividend Growth | 9 |
Payout Ratio | n/a |
Buyback Yield | 0.88% |
Shareholder Yield | 5.82% |
Earnings Yield | -2.14% |
FCF Yield | 4.74% |
Stock Splits
The last stock split was on March 27, 2014. It was a forward split with a ratio of 5.
Last Split Date | Mar 27, 2014 |
Split Type | Forward |
Split Ratio | 5 |
Scores
Astellas Pharma has an Altman Z-Score of 1.92. A Z-score under 3 suggests an increased risk of bankruptcy.
Altman Z-Score | 1.92 |
Piotroski F-Score | n/a |